Journal of Cachexia, Sarcopenia and Muscle (JCSM) - Abstract


Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin

Stefan D. Anker, Andrew J. S. Coats, John E. Morley

A major component of the cancer anorexia-cachexia syndrome is a decline in food intake. Up until now none of the drugs that improve appetite also improve skeletal muscle. Recent studies have suggested that the oral ghrelin-analog, anamorelin, increased food intake and muscle mass. Unfortunately, it does not increase muscle power. Its regulatory future is uncertain, although it has important clinical effects.
 

Anker, S. D., Coats, A. J. S., and Morley, J. E. (2015) Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin. Journal of Cachexia, Sarcopenia and Muscle, doi: 10.1002/jcsm.12063.